Press Releases

Read Regulatory and non-regulatory press releases

  • All
  • Non-Regulatory
  • Regulatory
Regulatory

Press Release Oncology Venture is issuing 2,255,639 shares under its existing convertible loan note agreement with Negma Group LTD and Park Partners GP

Regulatory

Press release Oncology Venture acquires full ownership of its PARP inhibitor (2X-121) program

Regulatory

Press Release Oncology Venture is issuing 1,574,803 shares under its existing convertible loan note agreement with Negma Group LTD and Park Partners GP

Regulatory

Press release Oncology Venture signs agreement to out-license two pipeline assets as part of prioritized portfolio strategy

Regulatory

Press release Oncology Venture is issuing 5,177,584 shares under its share subscription agreement with Global Corporate Finance

Regulatory

Press Release Oncology Venture terminates agreement with liquidity provider

Regulatory

Press Release Oncology Venture is issuing 2,255,639 shares under its convertible note agreement with Negma Group LTD and Park Partners GB

Regulatory

Press Release Oncology Venture calls first investment tranche of SEK 10 million under its share subscription agreement with Global Corporate Finance

Regulatory

Press Release Oncology Venture is issuing 751,879 shares under its convertible note agreement with Negma Group LTD and Park Partners GB

Regulatory

Press release Oncology Venture acquires full control of Dovitinib program

Regulatory

Company Announcement Oncology Venture Publishes Q1 2020 Report for the Period January – March 2020

Non-Regulatory

Oncology Venture A/S Invites Investors for Q1 2020 Report Conference Call

Regulatory

Press release Oncology Venture issues 1,952,475 new shares in connection with debt conversions

Regulatory

Correction: Press release Oncology Venture issues 1,952,475 new shares in connection with debt conversions

Regulatory

Press release Oncology Venture secures a US $5 million (50 million SEK) equity investment from a new US based investor

Regulatory

Minutes from Annual General Meeting 2020

Regulatory

Press release Oncology Venture to test activity of its PARP inhibitor, 2X-121, as a potential therapy for Coronavirus

Regulatory

Press Release Oncology Venture is issuing 925,925 shares under its convertible note agreement with Negma Group LTD and Park Partners GB

Regulatory

Notice to convene Annual General Meeting 2020

Regulatory

Press Release Oncology Venture draws down the first tranche under its Convertible note agreement with Negma Group LTD and Park Partners GB

Want to keep updated on news from Oncology Venture? Sign up to our press releases here: